Hims & Hers Health, Inc. Earnings Recaps
Q2 2026
Aug 12, 2026
Shares declined 3.4% as market participants reacted negatively to signs of deceleration in a key growth metric and cautious management tone despite strategic investments in AI. Investor concerns likely centered on the forward outlook ambiguities and the absence of explicit margin or revenue acceleration details.
Key takeaways
- Added over 300,000 subscribers in Q2, bringing total global subscriber base close to 3 million.
- Early rollout of AI-native platform for Hers weight loss customers led to tripled messaging engagement and 80% of questions handled by AI.
- AI implementation reduced nonclinical support workload by nearly 50%, improving operational efficiency.
- Management emphasized long-term technology-driven growth and global expansion but lacked clear near-term guidance or margin highlights.
- The cautious tone and potential deceleration in subscriber growth likely overshadowed operational gains, contributing to the stock’s negative reaction.
Q1 2026
May 13, 2026
Shares dropped 11.5% following earnings as investors reacted negatively to a cautious outlook on growth and margin pressures despite commentary on platform expansion and new product introductions.
Key takeaways
- Management highlighted progress in expanding therapeutic specialties and strategic initiatives, including a shift in the weight loss business towards a broader, globally unified approach.
- Adoption of GLP-1 products, including over 125,000 shipments of Wegovy within six weeks, showed initial demand strength but did not offset broader investor concerns.
- Expansion efforts include a planned acquisition of Eucalyptus to enhance global footprint across key markets like Australia, the U.K., Germany, Japan, and Canada.
- The company emphasized investments in data and technology, aiming for longer-term platform engagement and network effects.
- Despite these positives, investor reaction suggests skepticism about near-term growth acceleration and margin sustainability, as reflected in the significant decline in share price.
Q3 2025
Nov 4, 2025
Hims & Hers reported a robust Q3 2025, achieving nearly 50% year-over-year revenue growth driven by a 50% increase in subscribers using personalized health solutions, bolstered by strategic partnerships and innovations.
Key takeaways
- Subscribers utilizing personalized care solutions surged 50% year-over-year, underpinning revenue growth.
- Strategic partnerships with Novo Nordisk and Marius Pharmaceuticals aim to expand access to innovative treatments, including Wegovy.
- The company made a significant investment in GRAIL, enhancing its offerings in multi-cancer early detection.
- A strategic reduction in GLP-1 treatment prices by up to 20% aims to broaden care accessibility.
- Ongoing verticalization of compounding operations is expected to improve efficiency and quality in service delivery.